Amphastar Pharmaceuticals (AMPH) Releases Earnings Results, Beats Expectations By $0.02 EPS

Amphastar Pharmaceuticals (NASDAQ:AMPH) announced its quarterly earnings results on Tuesday. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02, Morningstar.com reports. The business had revenue of $89.69 million for the quarter, compared to the consensus estimate of $75.46 million. Amphastar Pharmaceuticals had a negative net margin of 2.33% and a positive return on equity of 2.80%.

NASDAQ AMPH opened at $21.37 on Wednesday. Amphastar Pharmaceuticals has a 52-week low of $14.40 and a 52-week high of $25.43. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.02 and a quick ratio of 1.34. The company has a market cap of $1.11 billion, a P/E ratio of 56.24, a price-to-earnings-growth ratio of 1.37 and a beta of 1.39.

A number of analysts recently weighed in on the stock. Needham & Company LLC downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday. Piper Jaffray Companies downgraded shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Wednesday. Zacks Investment Research raised Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 5th. BidaskClub raised Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, March 3rd. Finally, TheStreet raised Amphastar Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Friday, January 11th. Four investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $23.33.



In other news, insider Jason B. Shandell sold 7,500 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $24.99, for a total transaction of $187,425.00. Following the completion of the transaction, the insider now directly owns 175,818 shares of the company’s stock, valued at approximately $4,393,691.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO William J. Peters sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $25.36, for a total transaction of $38,040.00. Following the transaction, the chief financial officer now directly owns 77,050 shares of the company’s stock, valued at $1,953,988. The disclosure for this sale can be found here. Over the last three months, insiders have sold 252,442 shares of company stock valued at $5,545,389. 31.50% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its stake in shares of Amphastar Pharmaceuticals by 4.7% during the 3rd quarter. BlackRock Inc. now owns 5,987,805 shares of the company’s stock worth $115,205,000 after acquiring an additional 267,622 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Amphastar Pharmaceuticals by 7.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,909,883 shares of the company’s stock worth $36,746,000 after acquiring an additional 140,350 shares in the last quarter. Teachers Advisors LLC grew its stake in shares of Amphastar Pharmaceuticals by 0.7% during the 3rd quarter. Teachers Advisors LLC now owns 566,984 shares of the company’s stock worth $10,909,000 after acquiring an additional 4,194 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Amphastar Pharmaceuticals by 6.7% during the 4th quarter. Bank of New York Mellon Corp now owns 447,128 shares of the company’s stock worth $8,898,000 after acquiring an additional 28,225 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Amphastar Pharmaceuticals by 9.5% during the 4th quarter. Geode Capital Management LLC now owns 425,301 shares of the company’s stock worth $8,462,000 after acquiring an additional 36,784 shares in the last quarter. 45.62% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Amphastar Pharmaceuticals (AMPH) Releases Earnings Results, Beats Expectations By $0.02 EPS” was originally reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://dakotafinancialnews.com/2019/03/13/amphastar-pharmaceuticals-amph-releases-earnings-results-beats-expectations-by-0-02-eps.html.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Featured Story: What are the benefits of a balanced fund?

Earnings History for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.